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Coordinating an Oncology Precision Medicine Clinic Within
an Integrated Health System: Lessons Learned in Year One
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Abstract	Precision medicine is a term describing strategies to promote health and prevent and treat disease
based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology precision medicine
(OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations.
Implementation of an OPM clinical program optimally involves the support and collaboration of multiple
departments, including administration, medical oncology, pathology, interventional radiology, genetics,
research, and informatics. In this review, we briefly introduce the published evidence regarding OPM’s
potential effect on patient outcomes and discuss what we have learned over the first year of operating
an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI)
comprised of multiple hospitals and clinics. We also report our experience implementing a specific
OPM software platform used to embed molecular panel data into patients’ electronic medical records.
(J Patient Cent Res Rev. 2019;6:36-45.)
Keywords	oncology; precision medicine; integrated health system; community; genomics

What Is Oncology Precision Medicine?
Precision medicine is a buzzword in contemporary
health care. Buzzwords are popular because they
encapsulate complex information into simpler
terminology, but they also can become overused, fail
to convey appropriate complexity or nuance, and result
in miscommunication. If precision medicine is defined
broadly enough, it could be equated with medicine in
general and loses any real meaning. More specifically,
precision medicine refers to personalized therapy based
on each person’s DNA and other unique characteristics.
The National Institutes of Health’s Precision Medicine
Initiative aims to gather genetic and health data on 1
million individuals to study how those characteristics
may be used to prevent or treat disease.1

Correspondence: Michael A. Thompson, MD, PhD, FASCO,
Aurora Research Institute, 960 N. 12th Street, Room 4111,
Milwaukee, WI 53233 (michael.a.thompson@aurora.org)

36

JPCRR • Volume 6, Issue 1 • Winter 2019

The concept of oncology precision medicine (OPM)
also has varied definitions and is commonly used in
association with terms such as personalized medicine,
genomic medicine, and individualized medicine
(Table 1). Herein, we use OPM to refer to molecularly
driven therapy choices — including immunotherapy
based on biomarkers — applied to individuals. Health
practitioners have always tried to personalize therapy
by evaluating the patient as a whole (holistic) and in
context with age, comorbidities, and family history.
We are now increasingly using molecular information
as an additional factor to define individualized
treatment options.
Why Pursue OPM?
Basing cancer treatment on biomarkers or tumorspecific genetic alterations is not new in oncology.
There are multiple examples of molecular biomarkers
and tumor-specific genetic alterations leading to standardof-care cancer treatment: hormone receptor expression
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Table 1. Synonyms for “Precision Medicine”
(used in Oncology)
Accurate medicine
Cancer genomics
Genetic medicine
Genetic profiling
Genetic testing
Individualized medicine
Molecular-guided therapy
Molecular-guided personalized medicine
Oncology precision medicine
Personalized medicine
Pharmacogenetics
Pharmacogenomics
Precision medicine
Precision oncology
Targeted therapy

and HER2 amplification in breast cancer; EGFR and
BRAF mutations, ALK and ROS1 fusions, and PDL1 expression in lung cancer; BRAF mutations in
melanoma; BRAF, KRAS, and NRAS mutations in
colorectal cancer; and others. An elegant example of
OPM is the development of imatinib to treat chronic
myelogenous leukemia associated with the BCR-ABL
fusion gene. This translocation results in constitutive
activity of the ABL oncogene. Imatinib is a tyrosine
kinase inhibitor that blocks ABL and reverses the
malignant phenotype.
Providing OPM to patients typically involves
comprehensive somatic tumor profiling and
tumor biomarker analysis in those with metastatic
malignancy and limited treatment choices to identify
rare or unexpected, often tumor-agnostic, treatment or
clinical trial options. In this setting, OPM treatment
recommendations may include Food and Drug
Administration (FDA)-approved therapies in a different
tumor type (off-label), on- or off-protocol experimental
therapies, or theoretical treatment considerations based
on preclinical models.
Multiple studies have evaluated the results of
OPM approaches (Table 2),2-12 and increasingly
the inclusion criteria of new clinical trials include
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molecular alterations. Supportive evidence includes
findings by Von Hoff et al,3 Radovich et al,4 and Haslem
et al,8,9 all of whom reported gains in progression-free
survival through use of molecular-based therapy. Metaanalyses by Schwaederle et al5,6 noted similar benefits
to OPM approaches, including improved response rates.
Conversely, criticisms of OPM are generally directed at
its use in patients with metastatic, treatment-refractory
disease, namely, that OPM marketing hype may take
advantage of the desperation and need for hope in patients
and families with advanced cancers. In an editorial
published in Journal of Clinical Oncology, Howard
(Jack) West noted a “fear that our current oncology
community will be guilty of hubris and of overpromising
what we can deliver in a realistic time line.”13 West cited
cautionary results from a pair of studies, the BATTLE-214
and the French SHIVA trial,2 the latter of which found no
progression-free survival or overall survival benefit in
patients treated based on molecular profiling (using drugs
available at that time in France). However, Tsimberidou
and Kurzrock questioned SHIVA’s findings, noting study
weaknesses such as the use of limited drugs and limited
targets, which is not consistent with current OPM clinical
trial designs.15
There are many examples of OPM clinical trials — some
of historical or ongoing interest are described in Table 3
— and the National Cancer Institute (NCI) has expanded
the number of OPM trials. These trials may have had and
still have barriers to accrual, but as OPM panel testing
becomes more pervasive, these trials are increasingly
becoming the new normal. Because of the rarity of
specific molecular alterations (which may be somatic
or germline), randomized clinical trials do not allow for
appropriately rapid evaluation of the utility of targeted
medications in this setting. As such, novel ways to share
information about patient response are warranted.
In 2017, Aurora Health Care (Milwaukee, WI) launched
an OPM clinic to serve its integrated health system,
which includes hospitals and clinics located across
eastern Wisconsin and northern Illinois; the launch
and implementation of this program was previously
reported.16 In this follow-up work, we describe the lessons
learned by clinicians, administrators, and research staff
in the clinic’s first year of operation for the purpose
of informing other health systems of the potential
outcomes an in-house OPM clinic may produce.
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Table 2. Selected Oncology Precision Medicine (OPM) References, Terms, and Findings
Total

MP

On MP
drug
Overall

Von Hoff et al
(2010)

106

86

66

+

PFSnew/PFSold ratio as an intrapatient metric; 27% of
OPM-treated patients had a PFS ratio of 1.3.

Le Tourneau et al2
(2015)

741

293

99

-

SHIVA study: druggable molecular alteration. No PFS
or OS benefit using a limited set of targets and drugs in
France.

Schwaederle et al5
(2015)

32,149

8078

8078

+

Meta-analysis of 570 studies and 32,149 patients on phase
II, single-agent arms revealed that, across malignancies,
a personalized strategy was an independent predictor
of better outcomes and fewer toxic deaths. In addition,
nonpersonalized targeted therapies were associated with
significantly poorer outcomes than cytotoxic agents, which
in turn were worse than personalized targeted therapy.

Schwaederle et al6
(2016)

13,203

–

–

+

Meta-analysis of 346 phase I clinical trials with 13,203
patients. OPM-based therapy resulted in improved ORR
and PFS. DNA biomarker-driven therapy had higher ORRs
compared to protein biomarkers. Studies that used targeted
agents without a biomarker-based selection strategy had
negligible response rates.

Radovich et al4
(2016)

168

44

19

+

PFS ratio ≥ 1.3 in 43.2% in MP vs 5.3% in non-MP treated
with nongenomically guided therapy (P<0.0001).

Haslem et al8
(2017)

72

36

36

+

Matched cohort study in the community setting. PFS
hazard ratio of 0.47 showing OPM benefit. MP patients had
lower patient costs per PFS week than the control group.

Reference
3

Dureau et al7 (2017)

Haslem et al9
(2018)

Findings

2018 updated data showed similar benefits for OS.

Ammakkanavar
et al11 (2017)

209

69

54

+/-

Economic costs need to be considered. Panel MP tests
need to acknowledge prior standard-of-care testing
(eg, extended RAS testing in colorectal cancer). Patient
selection is important. There was change in management
for 27% of patients based on OPM findings.

Tredan et al12
(2017)

2490
(1826
tested)

940

101

+

ProfiLER study. Actionable MP in 51% of patients, with
treatment recommendation in 35%. Most patients treated
derived benefit from the recommended molecular targeted
therapies, but these represent a minority of the whole
population screened.

Merker et al10
(2018)

–

–

–

+/-

ASCO/CAP literature review showed discordance with
ctDNA assays and genotyping tumor specimens. There
was no evidence of clinical utility and little evidence of
clinical validity of ctDNA assays in early-stage cancer,
treatment monitoring, or residual disease detection. There
was no evidence of clinical validity and clinical utility to
suggest that ctDNA assays are useful for cancer screening,
outside of a clinical trial.

ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; ctDNA, circulating tumor DNA;
MP, molecular panel; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
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Table 3. Examples of Oncology Precision Medicine Studies
Open

N

Sponsor

Title/NCT

11/2006–
(ANR)

250

MDACC

BATTLE: A Biomarker-Integrated Study in Chemorefractory Patients
With Advanced Non-Small Cell Lung Cancer (NCT00409968)

2/3/18–

217

MDACC

BATTLE 2: A Biomarker-Integrated Targeted Therapy Study in
Previously Treated Patients With Advanced Non-Small Cell Lung
Cancer (NCT03225664)

3/2010–

1920

QuantumLeap

I-SPY 2 Trial: Investigation of Serial Studies to Predict Your
Therapeutic Response With Imaging And moLecular Analysis 2
(NCT01042379)

3/2013

Varies

Novartis

Signature (http://www.trials.novartis.com)

6/16/14

10,000

NCI

Lung MAP: A Biomarker-Driven Master Protocol for Previously Treated
Squamous Cell Lung Cancer (NCT02154490)

8/18/14–

8300

NCI

ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification
and Sequencing Trial (NCT02194738)

8/12/15–

6452

NCI

MATCH: Molecular Analysis for Therapy Choice (NCT02465060)

3/2016–

1060

ASCO

TAPUR: Targeted Agent and Profiling Utilization Registry
(NCT02693535)

11/2016–

100,000

Strata Oncology

Profiling Biospecimens From Cancer Patients to Screen for Molecular
Alterations Related to Treatment Selection (NCT03061305)

ANR, active, not recruiting; ASCO, American Society of Clinical Oncology; MDACC, M.D. Anderson Cancer Center;
NCI, National Cancer Institute.

Systemwide Oncology Overview
Within the Aurora system, over 8000 new analytic
cases are diagnosed and approximately 25,000 patients
are served annually. As of this writing, the system
encompasses 154 oncology physicians (including
cancer-dedicated surgeons) and 11 genetic counselors.
There are 19 medical oncology and 11 radiation
oncology treatment locations. Approximately 180
cancer clinical trials are open or in follow-up, with
more than 1100 patients on cancer clinical trials.
Aurora is designated as an NCI Community Oncology
Research Program (NCORP) site.
OPM Clinic: Initial Progress
After development of OPM workflow and program
resources,16 the OPM clinic’s first molecular tumor
board (MTB) conference was held in March 2017.
Although we anticipated reviewing 50 cases in the first
12 months, 100 referred patients were reviewed by
November 2017. While our program is led by a medical
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oncologist and oncology pharmacist, OPM patient
care routinely involves several departments: nursing,
research, pathology, genetic counseling, radiation
oncology, and diagnostic and interventional radiology.
In January 2018, a nurse program coordinator was
hired as a shared full-time employee with the system’s
preestablished hereditary cancer prevention and
management program.
The clinic has amassed a database of educational slides
and articles on OPM. Initial foundational resources
included published study findings by Von Hoff et
al (2010),3 Radovich et al (2016),4 and Haslem et al
(2017, 2018 update);8,9 the Hoosier Cancer Research
Network’s phase II clinical trial (BRE12-158) of
genomic therapy after preoperative chemotherapy
in patients with triple-negative breast cancer;17 the
recent joint consensus statement by the American
Society of Clinical Oncology (ASCO), Association for
Molecular Pathology (AMP), and College of American

www.aurora.org/jpcrr
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Pathologists (CAP) on standardizing interpretation
and reporting of sequence variants in cancer;18,19 and
published works from Burkard et al20 and Thomas
Brown21 on community-based MTBs. Additional topics
continue to be explored in a journal club format as
they arise during case management. Examples include
Lynch syndrome and microsatellite instability testing,
molecular tumor burden and DNA polymerases, and
molecular alterations in prostate cancer.
OPM Clinic: Operations
As of November 2017, all comprehensive molecular
panel (MP) tests performed in Aurora’s oncology
system are required to be ordered by OPM staff through
a centralized process. This includes genomic tests from
vendors Foundation Medicine (Cambridge, MA), Caris
Life Sciences (Irving, TX), Paradigm Diagnostics
(Phoenix, AZ), Guardant Health (Redwood City,
CA), and Sysmex Inostics (Mundelein, IL), among
others. The primary driver of this centralization was to
reduce the financial risk to the patient or to the health
system associated with inappropriate testing or lack of
prior authorization. The centralized ordering process
ensures that the appropriate test is performed on an
appropriate patient on an appropriate tumor sample or
blood specimen. This practice also allows for better
understanding, oversight, and standardization of
testing practices within the system.
When an oncologist decides to order one of the above
tests, he or she has two options. In the first option, the
oncologist enters an order template in the electronic
medical record (EMR) for “Oncology Genomic Profile
Comprehensive” (Figure 1A). Within this orderable,
the oncologist selects the type of test to be performed
and notes the preferred test specimen. These data are
then deposited in a newly created field in the EMR
(Figure 1B). Use of this orderable generates a task and
notification for OPM staff in the EMR. The OPM team
reviews the order for appropriateness and completes
the test order through the requested company. If
deemed inappropriate, clinic member calls the referring
physician to discuss whether the test should or should
not be done.
The second option is for oncologists to refer patients to
the OPM clinic to coordinate the entire testing process. In
that scenario, the OPM team is responsible for selecting
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the type of test to be conducted and the test specimen.
To facilitate this, the patient meets with the OPM
team at a single centralized location (within the health
system) for a 1-hour visit. During this visit a physician
introduces the concepts of test selection, test turnaround
time, potential for test failure, financial implications of
testing, risk of potential germline findings, what results
could mean for treatment (“actionability”), and access
to on- or off-trial treatments based on results. Following
the visit a molecular test is ordered for the patient by
OPM staff using either archived tissue or a new biopsy.
In the case of coordinating a new biopsy, OPM staff is
responsible for entry of the “Oncology Genomic Profile
Comprehensive” order.
Once completed, all MP test results are routed to
OPM staff electronically by the testing companies.
OPM staff is then responsible for linking the PDF of
the results directly to the “Oncology Genomic Profile
Comprehensive” order. This allows for the tests to be
stored in a consistent location within the EMR (Figure
1B) and routes results to the ordering oncologist. As
of July 2018, all MP test results are automatically
reviewed by the MTB. Each week, resulted cases are
discussed at the OPM MTB conference. There are two
main topics considered for each case: what treatment
options exist for the patient based on MP results, and
whether a referral for germline confirmatory testing is
needed. A recommendation summary note is generated
within the EMR and routed to the referring oncologist
and treatment team. Treatment recommendations are
classified based on levels of evidence as suggested by
ASCO, AMP, and CAP.19
The primary oncologist also has the option to refer
the patient to the OPM clinic after MP testing for
discussion of the results. In this case the patient meets
with the OPM team at the same centralized location
for a 30-minute visit. The focus of this visit is on
what the test results mean for the patient’s treatment
and whether or not there are potential germline
considerations. Following case presentation to the
MTB or an OPM clinic visit, the final treatment
decisions are guided by the referring oncologist.
However, if an oncologist decides to pursue a targeted
treatment based on an MTB recommendation, OPM
staff will help with acquisition of off-label medications
through insurance companies or drug manufacturers.
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A

B

Figure 1. Electronic

medical record (EMR)
orderables and data.
Panel A: Orderable in the
EMR for “Oncology Genomic
Profile Comprehensive.”
Panel B: Oncology genomic
profile data is shown in
the EMR under Results ->
Pathology -> Molecular.

If a patient will be enrolled in a clinical trial, OPM
research staff will work with the research staff at the
treating site to ensure a smooth transition.
Biopsy and Billing
To determine tissue source for testing, the OPM clinic
works closely with pathology before, during, and after
the MTB conference to discuss the diagnosis, including
other molecular and nonmolecular testing not part of
the MPs chosen, and to determine adequacy of tissue
samples. Radiology and, in particular, interventional
radiology pre-review the most current images to
evaluate accessibility and the best lesion to biopsy.
There remains a tension for the interventional
radiologist performing a biopsy between the
philosophy of “diagnosis” and getting the minimum
tissue necessary to prevent complications versus
obtaining adequate tissue for OPM studies. Some have
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suggested that rebiopsy in advanced cancer should be
performed more often.22
In general, our OPM clinic makes the following
recommendations: 1) New tissue is preferred over older
tissue, although there are not enough data on duration
of time or number or type of intervening therapies to
be dogmatic; 2) Metastatic sites are preferred; 3) Solid
tissue is preferred over liquid biopsies –– especially given
recent studies on the lack of liquid biopsy concordance
with tissue, circulating tumor DNA (ctDNA), or cellfree DNA;10 and 4) Avoid zinc formalin process and
bone samples, as the processing can interfere with
molecular testing.23,24 In addition, tissue obtained
from bone and common decalcification procedures
may seriously affect DNA/RNA-based testing;
whereas ethylenediaminetetracetic acid (EDTA)based decalcification may be preferred for nucleic acid
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extraction. Testing, including liquid biopsy testing, is a
dynamic process that needs constant reevaluation.
MP tests ordered are screened for the Centers for
Medicare & Medicaid Services (CMS) date of service
policy, or “14-day rule.”25 This regulation requires that
if a biopsy or blood specimen is obtained and sent for
MP testing in the 14 days following the procurement,
the testing company must bill the institution that
performed the biopsy and is not able to bill the
patient’s insurance company. As such, institutions
were generally required to wait 14 days after biopsy or
blood draw to submit a genomic panel test order to a
test company so that patient insurance could be billed,
resulting in unnecessary delays in care. As of January 1,
2018, this is no longer applicable for patients who have
biopsies or blood draws performed in the outpatient
setting.26 The 14-day rule is still in effect for patients
with biopsies obtained in the inpatient setting and for
non-next generation sequence testing procedures.
The billing process surrounding MP testing is
extremely complex, and it can be difficult to convey to
patients what their potential out-of-pocket costs might
be. Some tests or insurance companies require prior
authorization, though there is not a universal process
and the means of completion is unique to each test
vendor or insurance company. MP testing is typically
not well-covered by insurance companies; however, on
March 16, 2018, CMS finalized approval of coverage
of their first MP test,27 which may change the future of
this landscape. For patients without insurance coverage
of MP testing, all test companies offer some degree
of financial assistance. In our experience, cost to the
patient has not been a significant barrier to testing.
For example, of 216 Aurora patients who received
testing by Foundation Medicine between July 2017
and July 2018 and who completed financial assistance
applications, 163 were rewarded 100% financial
assistance while an additional 20 patients received
either 80% or 90% coverage.
Role of OPM Data Software
It is possible to conduct an OPM MTB review with
paper and pencil or an off-the-shelf electronic database.
However, we felt it was critical to have the molecular
data embedded in the EMR in a way that they
would be retrievable during the course of a patient’s
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treatment and follow-up period. Therefore, our OPM
clinic purchased a software product (Syapse, San
Francisco, CA) to allow data transfer from different
testing companies or labs, conversion of PDF data into
discrete data points, and access to the product’s sharing
network, which compiles outcomes data (such as drug
response) from patients at all organizations utilizing
the product.16 A fully functional sharing network
could allow interoperability across participating health
systems by providing uniform structured information
to allow for aggregating cancer genomics data.28 Our
perceived shortcomings of Syapse’s current platform
include an inability to embed the discrete data directly
into the EMR and the slow availability of a clinical
trials matching program.
An MP’s “reported actionability” by molecular
testing companies is often not realized as “pragmatic
actionability” in the real-world setting. A normalized
data collection and analysis process allows evaluation
of concordance among MP therapy recommendations,
treatment orders, treatment rate, and clinical
outcomes.29 This should aid in understanding barriers
to implementation of OPM as well as identifying
areas of heterogeneous value in OPM testing. We
have experimented with various reporting metrics for
internal and external use. Figure 2 depicts a CONSORTlike diagram of MP data flow using data from 2018.
Although a significant proportion of our patients are
not receiving the recommended treatment (frequently
due to the decision to save therapies for later potential
progression), this is not unexpected compared with
other OPM programs.cf.20
Other metrics can evaluate utilization of MP tests,
stage use, and physicians ordering the test.
Future Program Goals
With our OPM centralized ordering system, weekly
OPM MTB conference, and OPM clinic now
established, we are looking to take the next steps. In
the future we intend to evaluate:
• Multiple outcomes metrics such as response rate,
progression-free survival ratio, health economic
data, and more. We also want to look at what
happened after we moved from a referral system to
a full “denominator” of testing to be more systemic
in nature.
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Figure 2. Oncology precision medicine molecular tumor board (MTB) and clinic outcomes at the reviewed health
system in 2018.

•
Actionable alterations versus variants of unknown
significance, or VUS (ie, variants that may have
significance but are not profiled as such in databases29).
• Genetic counseling referral patterns.
• Alteration allele percentages as a surrogate for the
gold standard of matched host and tumor DNA.
•
Deeper dive into selected individual cases,
including expanded testing such as exome or
whole genome sequencing and other omics (RNA,
protein, methylation, microbiome) with sequential
testing, to improve our understanding of systems
biology and mechanisms of resistance.
• Patient-centered feedback about the OPM process.
• Clinical decision support to systematize beyond the
MTB and beyond one health system.
• Expansion into noncancer areas such as cardiology,
obstetrics, and behavioral health.

Review

Conclusions
There are no prospective randomized controlled trials
establishing oncology precision medicine-based
treatment decisions as superior to routine care. However,
the most successful OPM treatments — targeted therapy
for non-small cell lung cancer or melanoma, tumoragnostic immunotherapy for microsatellite unstable
cancers, etc — are quickly adopted into standard of
care. There is considerable heterogeneity in clinical
results of studies evaluating OPM strategies. The ratio
of progression-free survival on MP-selected therapy
(PFSnew) to progression-free survival prior to MPselected therapy (PFSold) is a controversial intrapatient
metric for evaluation of OPM treatment benefit. There
is considerable controversy in the oncology community
regarding the value of, and future of, OPM, somewhat
sparked by its undeniably considerable visibility and
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often-exaggerated benefits, particularly when used as
a marketing tool.
That said, we created an OPM clinic and associated
molecular tumor board to attempt to achieve the
greatest possible value from OPM-based treatment.
Through this centralized approach, we hope to ensure
the appropriate patient is tested at the appropriate time
and testing is performed on the appropriate specimen.
Internal expertise for prioritizing therapeutic targets
and obtaining off-label or experimental therapeutics
has developed since the clinic’s launch. Identification
of FDA-approved therapies and clinical trial options
has grown more efficient, as has evaluation for germline
variants that may have treatment implications for the
patient and clinical implications for family members.
Finally, we also have been able to minimize financial
exposure for the patient and institution.

Patient-Friendly Recap
•H
 ope: Initial lessons learned from operating
an oncology precision medicine clinic inspire
optimism in this approach to identifying
targeted cancer therapies.
•H
 ype: There also is the potential that
marketing hype and genuine enthusiasm
among providers may mislead patients.
Expectations should be tempered with data.
• Be curious: Ask questions regarding available
care options.
• Be critical: Understand the evidence behind
decisions and potential benefit; understand the
risk of biopsy and potential financial burden.
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